$12.04
14.91%
Nasdaq, Nov 16, 11:39 am EST. Market open.
ISIN
US86627R1023
Symbol
SMMT

Summit Therapeutics PLC Sponsored ADR Stock News

Negative
●
Barrons
●
about 3 hours ago
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
Negative
●
Market Watch
●
about 4 hours ago
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Negative
●
Investors Business Daily
●
about 21 hours ago
The FDA said Summit Therapeutics' lung cancer drug ivonescimab, developed in China, failed to show a statistically significant survival benefit.
Neutral
●
Business Wire
●
one day ago
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), who...
Neutral
●
Business Wire
●
12 days ago
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on clinical and operational progress. “This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca's $2 billion strategic equity investment and the expansion of our net...
Neutral
●
Business Wire
●
22 days ago
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class investigational bispecific antibody ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tr...
Neutral
●
PRNewsWire
●
24 days ago
Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026 /PRNewswire/ -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tu...
Neutral
●
Business Wire
●
24 days ago
MIAMI & SEOUL, South Korea--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis in support of Summit's immuno-oncology development programs with ivonescimab. The effort will focus on applying Lunit SCOP...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today